137 related articles for article (PubMed ID: 34780035)
21. Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer compared to other subtypes of breast cancer.
Bansal GJ; Santosh D
Indian J Radiol Imaging; 2016; 26(4):475-481. PubMed ID: 28104942
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
23. Machine learning for diagnostic ultrasound of triple-negative breast cancer.
Wu T; Sultan LR; Tian J; Cary TW; Sehgal CM
Breast Cancer Res Treat; 2019 Jan; 173(2):365-373. PubMed ID: 30343454
[TBL] [Abstract][Full Text] [Related]
24. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
25. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
27. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging features in triple-negative breast cancer: comparison with luminal and HER2-overexpressing tumors.
Costantini M; Belli P; Distefano D; Bufi E; Matteo MD; Rinaldi P; Giuliani M; Petrone G; Magno S; Bonomo L
Clin Breast Cancer; 2012 Oct; 12(5):331-9. PubMed ID: 23040001
[TBL] [Abstract][Full Text] [Related]
29. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.
Howland NK; Driver TD; Sedrak MP; Wen X; Dong W; Hatch S; Eltorky MA; Chao C
J Surg Res; 2013 Dec; 185(2):697-703. PubMed ID: 24095025
[TBL] [Abstract][Full Text] [Related]
30. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
31. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
Tan DS; Marchió C; Jones RL; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2008 Sep; 111(1):27-44. PubMed ID: 17922188
[TBL] [Abstract][Full Text] [Related]
32. What are the characteristics of breast cancers misclassified as benign by quantitative ultrasound shear wave elastography?
Vinnicombe SJ; Whelehan P; Thomson K; McLean D; Purdie CA; Jordan LB; Hubbard S; Evans AJ
Eur Radiol; 2014 Apr; 24(4):921-6. PubMed ID: 24326756
[TBL] [Abstract][Full Text] [Related]
33. Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population.
Lim ST; Choi JE; Kim SJ; Kim HA; Kim JY; Park HK; Suh YJ
Breast Cancer Res Treat; 2016 Apr; 156(3):473-483. PubMed ID: 27041335
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
36. Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Liu X; Guan Y; Wang Y; Zhang W; Liu S; Wang L; Liu J; Niu Y
Tumour Biol; 2014 Sep; 35(9):8581-9. PubMed ID: 24863944
[TBL] [Abstract][Full Text] [Related]
37. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
Gorshein E; Klein P; Boolbol SK; Shao T
Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
[TBL] [Abstract][Full Text] [Related]
39. Multimodal ultrasound features of breast cancers: correlation with molecular subtypes.
Zhu JY; He HL; Jiang XC; Bao HW; Chen F
BMC Med Imaging; 2023 Apr; 23(1):57. PubMed ID: 37069528
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
